Peripheral Neuropathy and Mesenchymal stem/stromal cells (MSC): what the trial registry contains
The ClinicalTrials.gov registry holds 18 records for MSC in Peripheral Neuropathy: 5 recruiting now, 0 labelled Phase 3 or 4, across 6 countries. Snapshot 2026-08-29.
Why this is studied in Peripheral Neuropathy
Peripheral neuropathy covers diabetic, chemotherapy-induced and idiopathic nerve damage with very different prognoses. Cell rationales target microvascular support and nerve regeneration, and unlike the central nervous system, peripheral nerves do regenerate — slowly, and only if the underlying cause is controlled.
What MSC means in this table
Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.
The numbers
Every figure below comes from one reproducible query (peripheral neuropathy x mesenchymal stem cell) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 18 |
| Interventional studies in the sample | 16 |
| Recruiting right now | 5 |
| Completed | 5 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 or Phase 4 records | 0 |
| Countries with at least one site | 6 |
| Median planned enrolment | 30 participants |
| Largest single planned enrolment | 5,000 participants |
| First / most recent start year | 2005 — 2025 |
How mature is this evidence?
Nothing here carries a Phase 3 label yet, but the area is live: 5 of the 18 registered studies are enrolling now, so the picture will change over the next few years.
0 of these records (0%) were terminated, withdrawn or suspended, against 5 marked completed; unfinished studies rarely appear in marketing summaries.
| Phase label | Records | Share |
|---|---|---|
| Phase 1 | 10 | 45% |
| Phase 2 | 6 | 27% |
| Not applicable | 5 | 23% |
| Early Phase 1 | 1 | 5% |
Median planned enrolment is 30 participants (largest single study: 5,000). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Sites are spread across 6 countries, with China accounting for roughly 35% of country mentions — geography reflects where regulators permit this work and where sponsors sit, not where care is best.
| Country | Studies with a site there |
|---|---|
| China | 6 |
| South Korea | 4 |
| United States | 3 |
| Indonesia | 2 |
| Antigua and Barbuda | 1 |
| Germany | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
Among the top lead sponsors, 5 are universities or hospitals and 5 are companies, making this a evenly split area.
- Jie Shen — 3 records
- Hope Biosciences Research Foundation — 2 records
- ENCell — 2 records
- The Foundation for Orthopaedics and Regenerative Medicine — 1 record
- Ruhr University of Bochum — 1 record
- Cairo University — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07183761 — A Randomized Controlled Trial on the Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy in Subjects With Moderate to Severe Diabetic | Phase 2 | Recruiting | 140 | Min Long | 2025-10-01 |
| NCT06328712 — Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-c | Phase 1, Phase 2 | Recruiting | 27 | ENCell | 2024-05-30 |
| NCT04684602 — Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions | Phase 1, Phase 2 | Recruiting | 5,000 | Thomas Advanced Medical LLC | 2020-07-09 |
| NCT05152368 — Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells Exosomes for Trigeminal Neuralgia | Phase 1 | Recruiting | 20 | The Foundation for Orthopaedics and Regenerative Medicine | 2022-09-09 |
| NCT07723313 — Effectiveness of Amniotic Membrane Combined With Secretome as an Adjunct to Carpal Tunnel Release Surgery: Evaluation Using the Boston Carpal Tunnel Q | Early Phase 1 | Recruiting | 30 | PT. Prodia Stem Cell Indonesia | 2025-12-15 |
| NCT05507697 — Treatment With Human Umbilical Cord Mesenchymal Stem Cells for Refractory Diabetic Peripheral Neuropathy | Phase 1, Phase 2 | Unknown | 42 | Wuhan Central Hospital | 2022-05-19 |
| NCT01216865 — Umbilical Cord Mesenchymal Stem Cells Injection for Diabetic Foot | Phase 1, Phase 2 | Unknown | 50 | Qingdao University | 2011-01 |
| NCT01065337 — Induced Wound Healing by Application of Expanded Bone Marrow Stem Cells in Diabetic Patients With Critical Limb Ischemia | Phase 2 | Completed | 30 | Ruhr University of Bochum | 2005-08 |
| NCT05947578 — The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease. | Phase 1 | Completed | 9 | Cellatoz Therapeutics, Inc | 2023-06-19 |
| NCT05333406 — Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A | Phase 1 | Completed | 9 | ENCell | 2022-02-22 |
What this page does and does not tell you
A registry is a plan repository. Counting entries tells you what people intended to study, which is a weaker thing than what they found.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many MSC studies for Peripheral Neuropathy are recruiting right now?
5 of 18 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is MSC an approved treatment for Peripheral Neuropathy?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 18 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on MSC for Peripheral Neuropathy?
0 of 18 records carry a Phase 3 or Phase 4 label and 5 are marked completed. Registrations run from 2005 to 2025.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Peripheral Neuropathy: cell-therapy evidence and registered trials
- How much does stem cell therapy for Peripheral Neuropathy cost? (2026)
- Peripheral Neuropathy stem cell therapy — your questions answered (2026)
- Peripheral Neuropathy: cell-therapy evidence by therapy class
- MSC vs PRP for Peripheral Neuropathy: what the registries show
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.